Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iStent infinite and iDose TR in POAG
NCT07228221Phase 4Recruiting
- Start
- Jan 2026
- Primary completion
- Aug 2031
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of travoprost in open-angle glaucoma (OAG). Primary endpoint: Intraocular pressure reduction from baseline at 12 months. Started Jan 2026; status: recruiting.
02
Drugs
travoprost
03
Conditions
open-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT07228221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07228221.